The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2018 | Immuno-oncology in renal cell carcinoma: new combinations are coming

Name: Immuno-oncology in renal cell carcinoma: new combinations are coming
Uploaded: 2018-10-19T00:00:00.000Z
Duration: 1 min 45 s
Description: Hans Hammers, MD, PhD, of the University of Texas Southwestern Medical Center, Texas, USA, discusses the immunotherapeutic landscape for renal cell carcinoma, including upcoming combinations. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Hans Hammers • 19 Oct 2018

ESMO 2018

Gastrointestinal Cancer Liver Cancer Avelumab Axitinib Ipilimumab Nivolumab Pembrolizumab

Hans Hammers, MD, PhD, of the University of Texas Southwestern Medical Center, Texas, USA, discusses the immunotherapeutic landscape for renal cell carcinoma, including upcoming combinations. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.